We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ABUS market cap is 583.35M. The company's latest EPS is USD -0.4059 and P/E is -7.88.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.69M | 5.01M | 4.45M | 2.15M | 1.53M |
| Operating Income | -17.41M | -18.66M | -21.56M | -20.59M | -19.36M |
| Net Income | -16.34M | -17.09M | -20.1M | -19.31M | -17.88M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M |
| Operating Income | -144.07M | -57.33M | -73.52M | -65.46M | -78.1M |
| Net Income | -153.72M | -75.87M | -88.39M | -69.46M | -72.85M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 191.22M | 176.82M | 158.64M | 144.4M | 150.29M |
| Total Liabilities | 47.31M | 42.13M | 39.3M | 38.38M | 35.65M |
| Total Equity | 143.92M | 134.69M | 119.34M | 106.02M | 114.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 105.54M | 137.08M | 204.49M | 195.42M | 144.4M |
| Total Liabilities | 32.79M | 35.11M | 35.05M | 58.57M | 38.38M |
| Total Equity | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -27.3M | -46.86M | -68.64M | -85.94M | -19.3M |
| Investing | 16.68M | 18.12M | 28.55M | 50.77M | 11.69M |
| Financing | 20.42M | 25.16M | 26.84M | 30.65M | 24.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M |
| Investing | 28.34M | -14.91M | -12.68M | -74.94M | 50.77M |
| Financing | 37.46M | 86.75M | 137.24M | 31.81M | 30.65M |
| Market Cap | 583.35M |
| Price to Earnings Ratio | -7.88 |
| Price to Sales Ratio | 31.65 |
| Price to Cash Ratio | 21.86 |
| Price to Book Ratio | 5.42 |
| Dividend Yield | - |
| Shares Outstanding | 179.49M |
| Average Volume (1 week) | 1.26M |
| Average Volume (1 Month) | 994.52k |
| 52 Week Change | 24.05% |
| 52 Week High | 3.64 |
| 52 Week Low | 1.69 |
| Spread (Intraday) | 0.14 (4.31%) |
| Company Name | Arbutus Biopharma Corporation |
| Address |
100 burnaby, british columbia V5J 5J8 |
| Website | https://www.tekmirapharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
